InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.59
(
0.26%
)
Bitcoin
63,526.26
(
1.13%
)
Post# of 261
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Joe Stocks

Send PM Follow Ignore
Followers 217
Posts 28308
Boards Moderated 2
Alias Born 02/24/2002

Joe Stocks

Member Level

Re: None

Wednesday, 03/12/2008 8:19:57 AM

Wednesday, March 12, 2008 8:19:57 AM

Post# of 261
DNDN - Dendreon: FDA To Amend SPA For Phase III Trial Of Provenge

By Saba Ali
Last update: 7:52 a.m. EDT March 12, 2008

Dendreon Corp. (DNDN) said the Food and Drug Administration agreed to amend Special Protocol Assessment for the Phase III IMPACT clinical trial of Provenge, cellular immunotherapy for the treatment of advanced prostate cancer. The Seattle biopharmaceutical company said the amended SPA accelerates the expected timing of the final IMPACT results by about one year.

Joe

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up